{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:17:36Z","timestamp":1794334656020,"version":"4.9.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,12]],"date-time":"2023-02-12T00:00:00Z","timestamp":1676160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.clml.2023.02.003","type":"journal-article","created":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T02:23:02Z","timestamp":1676082182000},"page":"e232-e239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["A Phase I Trial of Allogeneic \u03b3\u03b4 T Lymphocytes From Haploidentical Donors in Patients With Refractory or Relapsed Acute Myeloid Leukemia"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4274-3895","authenticated-orcid":false,"given":"Jan","family":"Vydra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7294-222X","authenticated-orcid":false,"given":"Emilio","family":"Cosimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Lesn\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard Sebastian","family":"Wanless","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan George","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9436-4267","authenticated-orcid":false,"given":"Angela","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6439-0795","authenticated-orcid":false,"given":"Emma Kate","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Leek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.02.003_bib0001","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3389\/fimmu.2018.00800","article-title":"Improving the efficiency of V\u03b39V\u03b42 T-cell immunotherapy in cancer","volume":"19","author":"Hoeres","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2023.02.003_sbref0002","doi-asserted-by":"crossref","first-page":"e27572","DOI":"10.4161\/onci.27572","article-title":"\u03b3\u03b4 T cells for cancer immunotherapy: a systematic review of clinical trials","volume":"3","author":"Fisher","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.clml.2023.02.003_bib0003","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41573-019-0038-z","article-title":"Translating gammadelta (\u03b3\u03b4) T cells and their receptors into cancer cell therapies","volume":"19","author":"Sebestyen","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clml.2023.02.003_bib0004","unstructured":"Zaremba T An adaptive study of the safety, tolerability and efficacy of autologous \u03b3\u03b4 T lymphocyte therapy (ImmuniCell\u00ae) in patients with advanced cancers which are refractory to current treatment or who have indolent disease for which immunotherapy may be beneficial. TC BioPharm Intern Rep. Unpublished. 2019."},{"key":"10.1016\/j.clml.2023.02.003_sbref0005","doi-asserted-by":"crossref","first-page":"16010","DOI":"10.1038\/nrdp.2016.10","article-title":"Acute myeloid leukaemia","volume":"2","author":"Khwaja","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.clml.2023.02.003_sbref0006","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.4049\/jimmunol.1103710","article-title":"Human V\u03b39V\u03b42 T cells specifically recognize and kill acute myeloid leukemic blasts","volume":"188","author":"Gertner-Dardenne","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.clml.2023.02.003_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.729085","article-title":"\u03b3\u03b4 T cells for leukemia immunotherapy: new and expanding trends","volume":"12","author":"Barros","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2023.02.003_sbref0008","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1080\/10428190903085951","article-title":"Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome","volume":"50","author":"Markov\u00e1","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.02.003_bib0009","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3109\/14653249.2010.515581","article-title":"Zoledronate-activated V\u03b39\u03b3\u03b4 T cell-based immunotherapy is feasible and restores the impairment of \u03b3\u03b4 T cells in patients with solid tumors","volume":"13","author":"Noguchi","year":"2011","journal-title":"Cytotherapy"},{"key":"10.1016\/j.clml.2023.02.003_bib0010","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/ijc.28372","article-title":"Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma","volume":"134","author":"Cui","year":"2014","journal-title":"Int J Cancer. Int J Cancer"},{"key":"10.1016\/j.clml.2023.02.003_bib0011","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jcyt.2012.12.004","article-title":"Ex vivo characterization of \u03b3\u03b4 T-cell repertoire in patients after adoptive transfer of V\u03b39V\u03b42 T cells expressing the interleukin-2 receptor \u03b2-chain and the common \u03b3-chain","volume":"15","author":"Izumi","year":"2013","journal-title":"Cytotherapy"},{"key":"10.1016\/j.clml.2023.02.003_bib0012","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/cam4.196","article-title":"Intraperitoneal injection of in vitro expanded V\u03b39V\u03b42 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer","volume":"3","author":"Wada","year":"2014","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2023.02.003_bib0013","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jcyt.2017.01.002","article-title":"Adjuvant combination therapy with gemcitabine and autologous \u03b3\u03b4 T-cell transfer in patients with curatively resected pancreatic cancer","volume":"19","author":"Aoki","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.clml.2023.02.003_sbref0014","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-12-45","article-title":"Successful adoptive transfer and in vivo expansion of haploidentical \u03b3\u03b4 T cells","volume":"12","author":"Wilhelm","year":"2014","journal-title":"J Transl Med"},{"key":"10.1016\/j.clml.2023.02.003_sbref0015","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/ijc.25791","article-title":"Elevated frequencies of CD4+ CD25+ CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia","volume":"129","author":"Shenghui","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2023.02.003_sbref0016","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1182\/blood-2016-07-730614","article-title":"MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia","volume":"129","author":"Pyzer","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.02.003_sbref0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103164","article-title":"Immune evasion mechanisms in acute myeloid leukemia: a focus on immune checkpoint pathways","volume":"157","author":"Taghiloo","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2023.02.003_bib0018","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1080\/14712598.2021.1857361","article-title":"Lymphodepletion strategies to potentiate adoptive T-cell immunotherapy\u2014what are we doing; where are we going?","volume":"21","author":"Bechman","year":"2021","journal-title":"Expert Opin Biol Ther"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023000381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023000381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:42:55Z","timestamp":1761871375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023000381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2152265023000381"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.02.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase I Trial of Allogeneic \u03b3\u03b4 T Lymphocytes From Haploidentical Donors in Patients With Refractory or Relapsed Acute Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}